Vinay Prasad

Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Prasad’s replacement is “likely to fall further along the ‘right-to-try’ arm of the MAHA-RFK policy side,” Leerink analyst Mani Foroohar said.
Angus Liu Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am
FDA
Favicon Fierce Pharma

FDA investigates 2 deaths after Sarepta Duchenne gene therapy

Jun 25, 2025 10:26am
FDA
Favicon Fierce Pharma

FDA's acting CDER head heads for the exit: report

Jun 23, 2025 1:48pm